Finasteride reduces the risk of incident clinical benign prostatic hyperplasia

European Urology

Volumn 62, Issue 2, 2012, Pages 234-241

  Parsons, J Kellogg ^a   Schenk, Jeannette M ^b   Arnold, Kathryn B ^b   Messer, Karen ^c   Till, Cathee ^b   Thompson, Ian M ^d   Kristal, Alan R ^b,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

5 reductase inhibitor; Finasteride; Prevention and control; Prostatic hyperplasia; Prostatic neoplasm

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; BODY MASS; CANCER PREVENTION; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FOLLOW UP; HAZARD RATIO; HUMAN; HUMAN EXPERIMENT; INTERNATIONAL PROSTATE SYMPTOM SCORE; MALE; NORMAL HUMAN; OUTCOME ASSESSMENT; PHYSICAL ACTIVITY; POST HOC ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RACE; SMOKING;

5-ALPHA REDUCTASE INHIBITORS; AGED; AGED, 80 AND OVER; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; RISK; TREATMENT OUTCOME;

EID: 84862886539     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2012.03.007     Document Type: Article

References (28)

1. C.S. Saigal, and G. Joyce Economic costs of benign prostatic hyperplasia in the private sector J Urol 173 2005 1309 1313 (Pubitemid 40380559)
2. J.T. Wei, E. Calhoun, and S.J. Jacobsen Urologic Diseases in America Project: benign prostatic hyperplasia J Urol 173 2005 1256 1261 (Pubitemid 40380548)
3. V. Kupelian, J.T. Wei, and M.P. O'Leary Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey Arch Intern Med 166 2006 2381 2387 (Pubitemid 44833365)
4. J.K. Parsons, J. Bergstrom, J. Silberstein, and E. Barrett-Connor Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years Urology 72 2008 318 321
5. G. Engstrom, L. Henningsohn, G. Steineck, and J. Leppert Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract BJU Int 95 2005 810 815 (Pubitemid 40547212)
6. B.C. Taylor, T.J. Wilt, and H.A. Fink Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study Urology 68 2006 804 809 (Pubitemid 44633362)
7. J.K. Parsons, J. Mougey, and L. Lambert Lower urinary tract symptoms increase the risk of falls in older men BJU Int 104 2009 63 68
8. V. Kupelian, M.P. Fitzgerald, S.A. Kaplan, J.P. Norgaard, G.R. Chiu, and R.C. Rosen Association of nocturia and mortality: results from the Third National Health and Nutrition Examination Survey J Urol 185 2011 571 577
9. G. Andriole, N. Bruchovsky, and L.W. Chung Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia J Urol 172 2004 1399 1403 (Pubitemid 39249729)
10. J.D. McConnell, C.G. Roehrborn, and O.M. Bautista The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia N Engl J Med 349 2003 2387 2398 (Pubitemid 37542987)
11. J.K. Amory, C. Wang, and R.S. Swerdloff The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men J Clin Endocrinol Metab 92 2007 1659 1665 (Pubitemid 46997168)
12. A.R. Kristal, J.M. Schenk, and Y. Song Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial Am J Epidemiol 168 2008 1416 1424
13. J.K. Parsons, K. Palazzi-Churas, J. Bergstrom, and E. Barrett-Connor Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study J Urol 184 2010 1040 1044
14. I.M. Thompson, P.J. Goodman, and C.M. Tangen The influence of finasteride on the development of prostate cancer N Engl J Med 349 2003 215 224 (Pubitemid 36859473)
15. G.L. Andriole, D.G. Bostwick, and O.W. Brawley Effect of dutasteride on the risk of prostate cancer N Engl J Med 362 2010 1192 1202
16. A.R. Kristal, C. Chi, C.M. Tangen, P.J. Goodman, R. Etzioni, and I.M. Thompson Associations of demographic and lifestyle characteristics with prostate-specific antigen (PSA) concentration and rate of PSA increase Cancer 106 2006 320 328 (Pubitemid 43100440)
17. A.R. Kristal, K.B. Arnold, and J.M. Schenk Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial J Urol 177 2007 1395 1400 quiz 1591 (Pubitemid 46436001)
18. A.R. Kristal, K.B. Arnold, and J.M. Schenk Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial Am J Epidemiol 167 2008 925 934 (Pubitemid 351521732)
19. Walsh PC. Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I.M. Thompson, Jr., C.M. Tangen, J.J. Crowley, L.G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006. J Urol 2006;176:2744, author reply 2744.
20. I.M. Thompson, C.M. Tangen, and M.S. Lucia The Prostate Cancer Prevention Trial and the future of chemoprevention BJU Int 101 2008 933 934 (Pubitemid 351422566)
21. T.J. Wilt, R. Macdonald, and K. Hagerty 5-alpha-reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review BJU Int 106 2010 1444 1451
22. B.S. Kramer, K.L. Hagerty, and S. Justman Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline J Urol 181 2009 1642 1657
23. H.R. Superko, and S. King 3rd Lipid management to reduce cardiovascular risk: a new strategy is required Circulation 117 2008 560 568 discussion 568
24. K.A. Pearce, C.D. Furberg, B.M. Psaty, and J. Kirk Cost-minimization and the number needed to treat in uncomplicated hypertension Am J Hypertens 11 1998 618 629 (Pubitemid 28270727)
25. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007:CD002003.
26. J.K. Parsons, H.B. Carter, and A.W. Partin Metabolic factors associated with benign prostatic hyperplasia J Clin Endocrinol Metab 91 2006 2562 2568 (Pubitemid 44024618)
27. J.K. Parsons, A.V. Sarma, K. McVary, and J.T. Wei Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions J Urol 182 2009 S27 S31
28. K.T. McVary, C.G. Roehrborn, and A.L. Avins Update on AUA guideline on the management of benign prostatic hyperplasia J Urol 185 2011 1793 1803